{
  "abstract": "The 2025 update of the Association of British Neurologists guidelines for the management of autoimmune myasthenia gravis (MG) emphasises several points that are distinct from the 2015 guidelines based on recent research and publications. The main differences from the previous guidelines are: (1) The recommendation to prescribe daily steroids rather than the alternate day regimen is now standard practice. (2) There is a clear emphasis on the beneficial effects of early thymectomy. (3) Randomised controlled trial evidence now supports early use of rituximab (within 1 year of generalised disease onset), although the evidence is less robust, but still likely to be useful, in established treatment-refractory MG. (4) Finally, several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.",
  "authors": [
    {
      "affiliations": [
        "Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK",
        "Department of Neurology, University Hospitals Birmingham, Birmingham, UK"
      ],
      "name": "Saiju Jacob"
    },
    {
      "affiliations": [
        "Queen Elizabeth University Hospital, Glasgow, UK"
      ],
      "name": "Maria Elena Farrugia"
    },
    {
      "affiliations": [
        "Academic Neuromuscular Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK",
        "Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK"
      ],
      "name": "Channa Hewamadduma"
    },
    {
      "affiliations": [
        "Department of Neurology, King’s College Hospital, London, UK"
      ],
      "name": "Fiona Norwood"
    },
    {
      "affiliations": [
        "Neurology, Swansea Bay University Health Board, Port Talbot, Wales, UK"
      ],
      "name": "Marguerite Hill"
    },
    {
      "affiliations": [
        "Nuffield Department of Clinical Neurology, University of Oxford, Oxford, UK"
      ],
      "name": "Maria Isabel Leite"
    },
    {
      "affiliations": [
        "Department of Neurology, Queens University, Belfast and South East Health and Social Care Trust, Belfast, UK"
      ],
      "name": "John Paul McConville"
    },
    {
      "affiliations": [
        "Department of Neurology, Wessex Neurological Centre, Southampton General Hospital, Southampton, UK"
      ],
      "name": "Ashwin Arnold Pinto"
    },
    {
      "affiliations": [
        "University College London Hospitals NHS Foundation Trust National Hospital for Neurology and Neurosurgery, London, London, UK",
        "Department of Neurology, Guys and St Thomas’ NHS Foundation Trust, London, London, UK"
      ],
      "name": "Jennifer Spillane"
    },
    {
      "affiliations": [
        "Neurology, Salford Royal NHS Foundation Trust, Manchester Centre for Clinical Neuroscience, Greater Manchester, UK"
      ],
      "name": "Jon Sussman"
    },
    {
      "affiliations": [
        "Neurology, Imperial College Healthcare NHS Trust, London, London, UK"
      ],
      "name": "Stuart Viegas"
    }
  ],
  "title": "Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)",
  "uid": "b1dc7355-b5d0-5c51-b63a-6cdaeae08fe5"
}